BrainStorm appoints Nir Naor as Board member and Audit Committee chair; Taub resigns

BRAINSTORM CELL THERAPEUTICS INC.

Malcolm Taub resigned from Board effective June 15, 2023; decision not due to any disagreement with the Company.
Nir Naor elected to Board effective June 20, 2023, as new independent director, Audit Committee chair, and GNC Committee member.
Naor receives initial grant of 11,999 restricted shares plus annual stock option or restricted stock awards, vesting monthly over 12 months.
Naor has over 20 years of finance and biotech experience, including CFO of Arbor Pharmaceuticals and senior roles at UCB and AstraZeneca.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nir Naor

Director, Chair of Audit Committee

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2023-06-20
Filed: June 20, 2023, 7:59 PM ET

On June 19, 2023, the Board elected Nir Naor to serve as a member of the Board, effective June 20, 2023, filling the vacancy created by Mr. Taub’s resignation.

Departed

Malcolm Taub

Director

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2023-06-15
Successor: Nir Naor
Filed: June 20, 2023, 7:59 PM ET

On June 15, 2023, Malcolm Taub notified the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s Board, and all committees thereof, effective as of the close of business on June 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nir Naor was elected as Director, Chair of Audit Committee at BRAINSTORM CELL THERAPEUTICS INC..

Action: elected
Role: Director, Chair of Audit Committee

Exact text from the filing

On June 19, 2023, the Board elected Nir Naor to serve as a member of the Board, effective June 20, 2023, filling the vacancy created by Mr. Taub’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Malcolm Taub resigned as Director at BRAINSTORM CELL THERAPEUTICS INC..

Action: resigned
Role: Director

Exact text from the filing

On June 15, 2023, Malcolm Taub notified the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s Board, and all committees thereof, effective as of the close of business on June 15, 2023.

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-072950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.